Prague, Czech Republic, 09 August 2021 —The first implantation of the Minos® Abdominal Aortic Stent-Graft and Delivery System (Minos® Stent Graft System), a product developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) was completed in the Czech Republic. This marks the twelfth market that the Minos® Stent Graft System has entered, following its approval for use in China, Greece, Poland, Spain, Germany, Italy, Switzerland, Argentina, Croatia, Hungary and Brazil.
The implantation procedure was performed by a surgical team led by Drs. Pavel Prochazka and Jozef Kučerák from the General Faculty Hospital. Preoperative angiographic examination showed that the patient, a 73-year-old male, had a challenging abdominal aortic aneurysm of approximately 6 cm in diameter, which is complicated by calcification and severe stenosis of the access artery. The team selected the Minos® Stent Graft System for treatment and performed post-dilation of the branch stent using a balloon, as the ultra-low profile delivery sheath of the Minos® Stent Graft System provides a better solution for patients with complicated abdominal aortic anatomy. Angiography showed that the aneurysm was effectively isolated, the stent graft well conformed to the patient’s anatomy and the blood flow in the branch stent was restored, confirming the success of the operation.
Following the procedure, Drs. Prochazka and Kučerák commented, “The Minos® Stent Graft System features an ultra-low profile delivery sheath that is able to conform to the patient’s narrowed iliac artery. The system provided us a very smooth control experience throughout the procedure.”
The Minos® System features a three-piece design that enables flexible assembly to accommodate different size requirements. Its main body was constructed from a laser-cut M-stent with integrated barbs and covered with seamless woven graft, and its iliac limbs are woven by a single wire in a spiraling pattern. The advanced core technologies are able to meet the treatment needs of a wider range of abdominal aortic aneurysms with complex anatomy, which reduces the rate of complications such as device migration, endoleaks or occlusion, and thus minimizes the risk of long-term reintervention.
Minos® Stent Graft System has won the recognition of experts and demonstrated excellent performance in clinical applications in many countries across Europe and South America since its introduction. Endovastec™ will further enhance in-depth cooperation with international clinical experts, striving to promote more high-quality and innovative solutions for the treatment of aortic and peripheral vascular diseases, so as to benefit more patients worldwide.
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), which is a subsidiary of MicroPort Scientific Corporation (MicroPort®, 00853.HK), was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New “Little Giant” Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.